SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is actively trending as its community champions a "culture first" approach on the Solana blockchain, boldly claiming to be "like Bitcoin but way higher." The project's unique blend of cannabis culture, positivity, and long-term "bongterm" holding is sparking significant engagement, with supporters asserting its role as a key liquidity driver and organic growth catalyst for the broader Solana ecosystem.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is trending due to significant volatility after a prospective tenant terminated a key funding agreement for its AI data center project, coupled with news of a class-action lawsuit. Despite this setback, many in the community view the sharp decline as an overreaction, highlighting the company's long-term potential as a critical energy provider for power-hungry AI infrastructure and ongoing negotiations. Investors are keenly watching for further developments as the company aims to secure new contracts and participate in upcoming industry events.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash ($BCH) is generating significant community buzz, with many anticipating a major breakout, driven by its notable resilience during broader crypto market shifts and speculation around upcoming regulatory clarity for digital assets. Supporters are highlighting BCH's ongoing technological advancements, including post-quantum vault integration, as a key differentiator poised for substantial outperformance in an anticipated altcoin season. This has fueled a polarized debate, with some forecasting significant gains while others remain skeptical of its historical volatility.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following positive FDA feedback confirming a clear path for its lead drug Sonelokimab to a Biologics License Application submission without additional trials, significantly de-risking the asset. This pivotal development is fueling widespread community speculation about an imminent, high-value buyout by a major pharmaceutical company and the potential for a significant short squeeze. Investors are particularly focused on the drug's 

Aster is a next-generation decentralized perpetual exchange that combines non-custodial trading with advanced features like hidden orders and multi-chain support. The platform emerged from the merger of Astherus and APX Finance in late 2024, with APX token holders able to migrate their holdings to ASTER.  Aster addresses the gap between centralized and decentralized exchanges by enabling traders to maintain full control of their assets while accessing deep liquidity and CEX-grade trading tools. The platform supports trading of both cryptocurrency perpetuals and U.S. stocks with up to 100x leverage, all settled on-chain in crypto without requiring traditional financial infrastructure.  The platform offers two distinct trading modes to accommodate different user needs. Simple Mode provides one-click, MEV-resistant trading with up to 1001x leverage for beginners, while Pro Mode delivers a full order book with advanced features like automated grid trading and hidden orders that remain invisible until execution.   Aster operates across BNB Chain, Ethereum, Solana, and Arbitrum without requiring bridging, with liquidity pooled across markets to support large trades with minimal slippage. A distinctive feature allows users to deposit yield-generating assets like asBNB or USDF as collateral, earning passive returns while trading, maximizing capital efficiency compared to platforms where collateral sits idle.  Aster received backing from YZi Labs (formerly Binance Labs), which holds a minority stake through a private fund managing over $10 billion on behalf of early Binance executives. Changpeng Zhao, founder of Binance, serves in an advisory role and has personally invested over $2.5 million worth of ASTER tokens.   The ASTER token serves multiple functions including governance rights, staking rewards through liquidity provision, and earning incentives through the platform's points program for traders and liquidity providers.

ASTERION

ASTER is trending following significant endorsement and personal investment from CZ, fueling widespread community discussion about its potential as a next-generation decentralized exchange. Many anticipate substantial price surges, positioning ASTER as a strong competitor in the 'DEX wars' against platforms like Hyperliquid, though some voice concerns about potential manipulation.

Polygon

Polygon (POL) is actively trending due to significant increases in on-chain activity, robust revenue generation, and an active token burning mechanism, which is fostering scarcity. The community widely regards POL as undervalued, with many anticipating substantial gains by drawing parallels to past altcoin surges, while also discussing a potential return to its familiar MATIC ticker for enhanced brand recognition.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MicroAlgo (MLGO) is a hot topic following reports of its quantum entanglement-based AI algorithm and inclusion in an S&P Global index. Many investors highlight its stated profitability, substantial cash reserves, and significant locked-up shares as potential catalysts for a surge, while others remain wary of its history of dilution and concerns typical of Chinese small-cap stocks.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals is witnessing an extraordinary surge in price and trading volume, sparking widespread debate about whether its current run is a monumental short squeeze or a speculative pump. Community discussions are heavily influenced by the company's perceived pivot to blockchain-based assets under new management, as investors weigh this highly volatile shift against its pharmaceutical roots. Many are actively monitoring the ticker, scrutinizing its fundamentals amidst an explosive increase in market capitalization and questioning the sustainability of its parabolic movement.

SPDR S&P MIDCAP 400 ETF Trust - S&P MidCap 400 ETF

SPDR S&P Midcap 400 ETF Trust

The SPDR S&P Midcap 400 ETF Trust is trending as it achieves new all-time highs, signaling a potential expansion of market breadth beyond mega-cap stocks. Community discussions highlight its breakout as a positive indicator for overall market strength, noting that mid-cap companies often demonstrate greater financial viability. Many anticipate continued outperformance from this sector, with index rebalancing and robust fundamentals driving further interest.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is trending amid widespread community speculation about a potential acquisition, fueled by its upcoming presentation at the J.P. Morgan Healthcare Conference and strong commercial performance. Investors are highlighting the company's significant revenue growth, current profitability, and promising pipeline assets, viewing it as a compelling target for larger pharmaceutical players. Despite ongoing discussions of market manipulation, strong institutional ownership and a high short interest are intensifying bullish sentiment among followers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
